Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2020 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Mol Cancer Res. 2022 May 4;20(5):722-734. doi: 10.1158/1541-7786.MCR-22-0025.
Mol Cancer Res. 2022.
PMID: 35149545
Free PMC article.
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA.
Somwar R, et al.
Commun Biol. 2020 Dec 16;3(1):776. doi: 10.1038/s42003-020-01508-w.
Commun Biol. 2020.
PMID: 33328556
Free PMC article.
Item in Clipboard
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.
Suzawa K, et al.
Clin Cancer Res. 2019 Feb 15;25(4):1248-1260. doi: 10.1158/1078-0432.CCR-18-1640. Epub 2018 Oct 23.
Clin Cancer Res. 2019.
PMID: 30352902
Free PMC article.
Item in Clipboard
Cite
Cite